Try Calculator
← Back to Compound Library GH SECRETAGOGUES

Tesamorelin (GHRH Analog)

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) distinguished by a trans-3-hexenoyl group modification at the N-terminus. This 44-amino acid peptide represents one of the most extensively studied GHRH analogs in clinical medicine, with rigorous trial data demonstrating specific effects on visceral adipose tissue reduction. Unlike exogenous recombinant growth hormone (rhGH), which provides supraphysiological hormone levels and suppresses endogenous production, tesamorelin stimulates the anterior pituitary to secrete GH through physiological pathways. This preserves the natural pulsatile secretion pattern and maintains hypothalamic-pituitary feedback mechanisms.

When administered in research settings, it signals the pituitary gland to release endogenous growth hormone. That GH then drives downstream effects through IGF-1, influencing fat metabolism, tissue repair, and cellular signaling. Because it amplifies natural physiology instead of overriding it, tesamorelin has consistently shown fewer adverse effects than direct GH administration in clinical research.

Tesamorelin has been called the visceral fat peptide, and it is the most expensive growth hormone related peptide option out there. It works the same way as CJC-1295 and Sermorelin. Same pathway, same mechanism. But it is the only one with specific clinical data proving visceral fat reduction using CT scans.

The FDA approved tesamorelin in 2010 under the brand name Egrifta for a specific indication: reducing excess abdominal fat in adults with HIV who have lipodystrophy. It remains the only medication specifically approved for this condition. A newer formulation called Egrifta WR was approved in 2024, offering weekly reconstitution instead of daily. It is now being used off label for body recomposition and anti-aging.

Tesamorelin was developed by Theratechnologies, Inc. of Canada. Beyond its approved use, researchers have studied it for conditions including obesity, nonalcoholic fatty liver disease (NAFLD), insulin resistance, and cognitive function in older adults.

Unlike direct growth hormone injections, tesamorelin works by stimulating the pituitary gland to produce and release its own growth hormone. This approach preserves the natural pulsatile pattern of GH secretion and maintains physiological feedback mechanisms. The result is a more natural hormone profile compared to exogenous GH administration.

Tesamorelin is a controlled medication requiring a prescription. It is prohibited by the World Anti-Doping Agency (WADA) under the category of Peptide Hormones, Growth Factors, and Related Substances.

How It Works

Tesamorelin binds to the growth hormone-releasing hormone receptor (GHRHR) on somatotroph cells in the anterior pituitary gland. The GHRHR is a G protein-coupled receptor (GPCR) that, upon activation:

This mechanism preserves physiological regulation. The somatotrophs remain responsive to endogenous inhibitory signals, particularly somatostatin (somatotropin release-inhibiting factor, SRIF) from the hypothalamus, which tonically suppresses GH secretion between pulses.

To understand how tesamorelin works, you need to understand how your body’s natural GH- IGF-1 endocrine axis and its metabolic regulation. There is a two-stage process here that most people do not understand.

Stage 1: Growth Hormone Secretion

GH secretion from the anterior pituitary is regulated by dual hypothalamic signals:

pulsatile fashion, primarily during nocturnal slow-wave sleep. GHRH activates somatotrophs to secrete GH.

tonically inhibits GH secretion. The pulsatile pattern of GH release results from alternating dominance of GHRH (pulse) and somatostatin (interpulse suppression).

to the growth hormone secretagogue receptor (GHS-R1a) on somatotrophs and hypothalamic neurons. Ghrelin amplifies GHRH-induced GH secretion and is elevated during fasting states.

The largest GH pulses occur during the first few hours of nocturnal sleep, particularly during slow-wave (deep) sleep stages. Fasting enhances GH secretion through multiple mechanisms, including elevated ghrelin and reduced insulin (insulin inhibits GH secretion).

Stage 2: IGF-1 Production

GH exerts some direct metabolic effects (lipolysis, anti-insulin actions), but many of its anabolic and growth-promoting effects are mediated by insulin-like growth factor 1 (IGF-1). GH stimulates hepatic IGF-1 synthesis and secretion. IGF-1 circulates bound to IGF-binding proteins (IGFBPs), particularly IGFBP-3, which extends its half-life and modulates tissue delivery.

IGF-1 mediates:

levels)

The GH-IGF-1 Metabolic Paradox

There exists a temporal metabolic paradox:

conversion

Physiologically, this is resolved through circadian timing: nocturnal GH secretion during fasted sleep provides a several-hour GH pulse; upon waking and feeding, insulin rises and the liver converts circulating GH to IGF-1, which then exerts anabolic effects throughout the day.

Tesamorelin’s Role in This System

Tesamorelin mimics endogenous GHRH, amplifying the physiological GH secretory signal. By administering tesamorelin before bedtime in a fasted state, the protocol aligns with the natural nocturnal GH pulse, potentially augmenting it. The subsequent post-waking meal provides the insulin necessary for hepatic IGF-1 synthesis.

Important distinction: Tesamorelin activates only the GHRH pathway. It does not directly activate ghrelin receptors. This is why tesamorelin is sometimes combined with ghrelin receptor agonists (e.g., ipamorelin) to activate both pathways simultaneously, theoretically producing synergistic GH secretion.

Pharmacokinetics

Following subcutaneous injection, tesamorelin is rapidly absorbed. Peak plasma concentrations (Tmax) occur approximately 0.15 hours (9 minutes) after administration. The mean bioavailability is approximately 4% due to first-pass metabolism and enzymatic degradation. The terminal elimination half-life (t½) is approximately 26 minutes (range: 26-38 minutes across studies). Clearance is rapid, with a mean clearance rate of 11.4 L/h. The short half-life necessitates daily administration for sustained therapeutic effect.

Despite the short peptide half-life, tesamorelin induces a GH secretory pulse lasting 2-3 hours. Peak GH concentrations occur approximately 30 minutes to 1 hour post-injection. IGF-1 levels rise more gradually, typically reaching steady-state elevations after 2-4 weeks of daily administration. In clinical trials, IGF-1 levels increased 1.5- to 2.5-fold above baseline and stabilized within the age-appropriate normal range.

What IGF-1 Does

The released growth hormone circulates through the body and acts on target cells including adipocytes (fat cells), hepatocytes (liver cells), myocytes (muscle cells), and osteoblasts (bone cells). One of its most important effects is stimulating the liver to produce IGF-1. IGF-1 activates hormone sensitive lipase. That is the enzyme that breaks down fat for energy. It also drives muscle protein synthesis, collagen production, and bone density maintenance. IGF-1 crosses the blood-brain barrier, which means it supports cognitive function.

The Visceral Fat Question

You have heard tesamorelin called the visceral fat peptide. If it works the same way as CJC-1295 and Sermorelin, what makes it specifically target visceral fat?

The mechanism is identical. All GHRH analogs signal your pituitary to release growth hormone. That growth hormone increases IGF-1, and IGF-1 mobilizes fat through lipolysis. There is no special visceral fat receptor that tesamorelin hits that the others do not. The cascade is identical. Fat mobilization does not discriminate by location. When IGF-1 activates hormone sensitive lipase, it is breaking down fat stores. Visceral fat, subcutaneous fat, the mechanism is the same.

What is actually different is the clinical data, not the mechanism. The HIV lipodystrophy trials specifically measured visceral fat with CT scans over 26 weeks. That is what tesamorelin was studied for and developed for, and that is what got its FDA approval. CJC-1295 and ipamorelin were not studied that way. They were studied for sleep quality, recovery markers, general body composition, not CT scans of visceral adipose tissue specifically.

Sermorelin is older. It is only 29 amino acids compared to tesamorelin’s 44. It is less stable and it causes cortisol and prolactin spikes that tesamorelin does not.

Is tesamorelin actually better at reducing visceral fat or is it just the only one with CT scan data proving it in that specific population? The honest answer is we do not know because that comparison study does not exist. Could you get the same visceral fat reduction from CJC-1295 dosed consistently at 2 mg equivalent daily for 26 weeks? Probably. But we do not have that data to prove it.

Unlike exogenous growth hormone, tesamorelin preserves the pulsatile pattern of GH release. The pituitary still responds to normal feedback mechanisms, including inhibition by somatostatin. This means the body maintains regulatory control over hormone levels rather than being overwhelmed by constant supraphysiologic doses.

Research-Backed Benefits

Targeted Reduction of Visceral Fat

Tesamorelin is FDA-approved for HIV-associated lipodystrophy due to its ability to significantly reduce visceral adipose tissue (VAT)—the deep, metabolically harmful fat surrounding organs. Clinical trials demonstrate reductions in abdominal fat approaching 15–20%, a level rarely achieved through lifestyle or pharmaceutical interventions alone. Visceral fat is strongly associated with insulin resistance, inflammation, dyslipidemia, and cardiovascular risk. Reducing it has outsized metabolic benefits compared to subcutaneous fat loss.

Preservation of Lean Mass

While reducing fat, tesamorelin helps preserve lean body mass. This makes it valuable during cutting phases or caloric restriction when muscle loss is a concern. Growth hormone promotes protein synthesis and opposes the catabolic effects of dieting.

Improved Lipid Profile and Cardiovascular Markers

Studies show tesamorelin improves triglyceride levels and the ratio of total cholesterol to HDL cholesterol. In the HIV trials, triglycerides dropped by about 50 points on average and cholesterol reduced by about 30%. These changes may reduce cardiovascular risk factors associated with excess visceral fat. Beyond fat loss, tesamorelin has been shown to lower triglycerides, total cholesterol, and non-HDL cholesterol. Research suggests that for every ~15% reduction in visceral fat, triglyceride levels may drop by ~50 mg/dL, highlighting a meaningful link between fat redistribution and cardiovascular health .

Liver Health Support

Research in patients with nonalcoholic fatty liver disease shows tesamorelin reduces hepatic fat content by approximately 37 percent. It may also prevent progression of liver inflammation and fibrosis. This represents a promising application beyond its approved indication.

Natural Hormone Stimulation

By working through the body’s own GHRH receptors, tesamorelin maintains physiological feedback mechanisms. This results in more natural GH pulsatility compared to direct growth hormone injections.

Tissue Repair and Regenerative Signaling

Preclinical and clinical research indicates that GH and IGF-1 play roles in tissue regeneration, nerve repair, and recovery from injury. Tesamorelin’s ability to enhance this axis has made it a candidate of interest in studies involving peripheral nerve injury and tissue healing.

Emerging Cognitive and Brain Health Research

A study published in JCI Insight showed tesamorelin improved cognitive function and brain metabolism in older adults at risk for Alzheimer’s disease. Other research suggests it may improve executive function, working memory, and response inhibition in older adults, including those with mild cognitive impairment. Studies also show it may improve mitochondrial health and reduce inflammatory markers. This is why the anti-aging community has latched onto this peptide. IGF-1 declines with age and restoring it to mid-normal range seems to have protective effects. GHRH analogues, including tesamorelin, are being explored for their effects on brain metabolism and neurotransmitter balance. Controlled trials have shown improvements in executive function and verbal memory in individuals with mild cognitive impairment, potentially through modulation of GABA and brain metabolite signaling.

Body Image Improvement

Clinical trials report improved body image distress scores in patients using tesamorelin, reflecting the psychological benefits of improved body composition.

Clinical Evidence and Research-Supported Effects

1. Visceral Adipose Tissue Reduction (FDA Approval Basis) Study: Falutz et al. (2010) – Phase III trial in HIV-associated lipodystrophy

Publication: Journal of Acquired Immune Deficiency Syndromes

Design: Multicenter, randomized, double-blind, placebo-controlled study of 404 HIV-infected adults with excess abdominal fat (≥140 cm²). Participants received 2 mg tesamorelin or placebo daily for 26 weeks.

Key Findings:

L4-L5) vs -1.2% with placebo (p<0.001)

reaccumulation over subsequent months

Study: Grunfeld et al. (2007) – NEJM metabolic effects study

Publication: New England Journal of Medicine

Design: 412 HIV-infected patients randomized to 2 mg tesamorelin or placebo daily for 26 weeks

Key Findings:

intolerance developed in a subset of patients

2. Nonalcoholic Fatty Liver Disease (NAFLD) Study: Stanley et al. (2019) – NAFLD trial in HIV-infected patients

Publication: Annals of Internal Medicine

Design: Randomized, double-blind, multicenter trial of 61 HIV-infected adults with NAFLD. Participants received 2 mg tesamorelin or placebo daily for 12 months.

Key Findings:

measured by MRI)

histological improvement

3. Cognitive Function and Brain Metabolism

Study: Baker et al. (2012) – Effects on cognitive function in healthy older adults

Publication: JAMA Neurology

Design: Randomized, placebo-controlled trial in older adults with mild cognitive impairment

Key Findings:

Note: This research is preliminary and exploratory. Tesamorelin is not approved for cognitive enhancement, and additional large-scale trials are needed.

Dosing Protocol

FDA-Approved Protocol

least 2-3 hours post-prandial)

term maintenance therapy may be required to sustain benefits.

(e.g., 3-6 months on, 1-2 months off) lack supporting clinical evidence.

Alternative Off-Label Protocols

Lower-dose protocol:

Note: Lower doses and cycling protocols have not been formally studied in clinical trials. Efficacy at <2 mg daily is uncertain.

Combination Protocol with Ipamorelin

bed, fasted)

receptor (GHS-R1a) pathway. Concurrent activation of both pathways produces synergistic GH secretion. The ghrelin receptor agonist also suppresses somatostatin release, reducing interpulse inhibition of GH secretion.

RCTs. It is extrapolated from studies of other GHRH/GHRP combinations.

Contraindicated Combinations

These compounds bind to the same GHRHR and provide redundant signaling. Combining them is pharmacologically illogical and wasteful.

from exogenous GH or IGF-1 LR3 administration triggers negative feedback via increased hypothalamic somatostatin release. This suppresses pituitary responsiveness to GHRH signals. Arvat et al. (1997) demonstrated that exogenous GH administration inhibited GHRH-induced GH secretion by 86%. The combination negates the efficacy of tesamorelin.

Important Timing Considerations

Fasting requirement: Administer at least 2-3 hours after the last meal. Elevated glucose and insulin suppress GH secretion through:

Bedtime administration rationale: Aligns with the natural circadian peak of GH secretion during slow-wave sleep. The evening fasted state maximizes GH pulse amplitude. Upon waking and consuming breakfast, insulin rises and facilitates hepatic GH-to-IGF-1 conversion, optimizing the anabolic response.

Morning dosing alternative: Some individuals experience sleep disruption with evening tesamorelin administration. If this occurs, morning administration (fasted, 2-3 hours before breakfast) is an acceptable alternative, though it does not align with natural nocturnal GH peaks.

Concentration Calculations

Standard vial size: 5 mg tesamorelin per vial

Option 1: 2.5 mL reconstitution → 2 mg/mL concentration

Option 2: 2 mL reconstitution → 2.5 mg/mL concentration

Option 3: 1 mL reconstitution → 5 mg/mL concentration

Reconstitution

Materials Required

Tesamorelin vial (lyophilized powder) Bacteriostatic water (0.9% benzyl alcohol) Sterile syringe for reconstitution (3 mL or larger) Insulin syringes for administration (U-100, 0.5 mL or 1 mL) Alcohol swabs Sharps disposal container

Reconstitution Procedure

air dry.

the lyophilized powder. Direct injection can denature the peptide.

minutes).

particulates, do not use.

Side Effects and Adverse Reactions

Tesamorelin’s side effect profile has been extensively characterized in clinical trials.

Common Side Effects (>10% incidence in trials)

transient flushing. Occurs in the majority of patients. Typically mild-to-moderate and resolves within 10-20 minutes. Rotating injection sites reduces severity.

self-limiting. If persistent or severe, dose reduction may be necessary.

mediated sodium retention and increased vascular permeability.

carpal tunnel symptoms)

Metabolic Side Effects

treatment to ensure levels remain within age-appropriate normal ranges.

(antagonism of insulin signaling, increased lipolysis leading to elevated free fatty acids). Some patients develop impaired fasting glucose or worsening of pre-existing hyperglycemia.

metabolic syndrome, or family history of diabetes. Clinical trials showed a modest increase in diabetes incidence. Regular blood glucose monitoring is essential.

Less Common Side Effects

administration. If this occurs, consider switching to morning dosing (fasted, 2-3 hours before breakfast).

symptoms develop (numbness, tingling, weakness in the hand), reduce dose or discontinue.

breathing). Discontinue immediately if these occur.

Long-Term Safety Considerations

theoretically could stimulate growth of occult (undetected) malignancies. Clinical trials (duration up to 26 weeks) did not show increased cancer incidence. However, long-term data (years to decades) are lacking. Individuals with a history of cancer should not use tesamorelin.

via negative feedback, tesamorelin works through physiological pathways and preserves pituitary responsiveness. However, long-term effects on pituitary function have not been extensively studied.

Tesamorelin raises IGF-1 levels, which theoretically could stimulate growth of existing tumors. Individuals with a history of cancer should not use tesamorelin. Clinical trials have not shown increased cancer incidence, but caution is warranted. The clinical trials followed patients for 26 weeks. We do not have decades of data. That does not mean it is unsafe long term. It just means we need to be cautious and monitor. This is true for most peptides. The research is relatively new compared to older medications like testosterone.

Contraindications and Precautions

Do Not Use If You Have: Active cancer or history of any malignant tumor Pituitary gland disorders, surgery, or tumors History of radiation therapy to the head or brain Known hypersensitivity to tesamorelin or related compounds Pregnancy (FDA Pregnancy Category X: can harm the fetus) Use Caution With: Diabetes or prediabetes (monitor blood glucose closely) History of head injury or trauma Kidney or liver disease Heart disease or recent heart surgery Breathing problems or asthma Migraines or epilepsy Adrenal gland disorders

Drug Interactions

IGF-1, triggering hypothalamic somatostatin release. Somatostatin inhibits pituitary GH secretion in response to GHRH, rendering tesamorelin ineffective. Arvat et al. (1997) demonstrated 86% inhibition of GHRH-induced GH release following exogenous GH administration. Do not combine.

efficacy

adjustments

Comparative Overview: Tesamorelin vs. Sermorelin vs. Recombinant

GH

Parameter Tesamorelin Sermorelin Recombinant GH Structure 44 AA + hexenoyl 29 AA (GHRH 1- 191 AA (native GH) 29) Mechanism GHRH analog GHRH fragment Direct GH replacement FDA Approval Yes (HIV Previously approved Yes (multiple lipodystrophy) indications) Half-life ~26-38 minutes ~10-20 minutes ~3-4 hours Standard Dose 2 mg daily 200-500 mcg daily 1-4 IU daily Primary Use Visceral fat Anti-aging, body Multiple indications reduction comp

Success Tips

Administer Before Bed Fasted: Tesamorelin works best when injected 30 to 60 minutes before bed, fasted. Here is exactly why that timing matters. When you inject fasted before bed, you have low insulin and high ghrelin. This maximizes your growth hormone pulse. That growth hormone circulates for 2 to 3 hours overnight and is mobilizing fat while you sleep. Then when you wake up in the morning and eat breakfast, your insulin rises and your liver converts that circulating growth hormone into IGF-1. That IGF-1 then works for you all day for recovery, collagen production, and metabolic benefits.

This is the same logic as eating carbs after you train. You train hard, you get a growth hormone pulse. That GH is mobilizing fat for energy. Then you eat carbs post-workout, insulin spikes,

your liver converts that circulating growth hormone into IGF-1, and you are in a maximum anabolic state.

Morning dosing alternative: Some individuals experience sleep disruption with evening dosing. Morning administration (fasted, 2-3 hours before breakfast) is acceptable if nighttime causes issues.

Realistic Timeline

Minimum 6 months for maximum benefit.

Be Patient With Results

Clinical trials show significant fat reduction by 26 weeks. Expect gradual, steady progress rather than dramatic overnight changes. The first noticeable improvements often appear around 8 to 12 weeks.

Monitor Your Metrics

Track waist circumference, body composition, and how clothes fit rather than relying solely on scale weight. Visceral fat loss may not translate directly to pounds lost if lean mass is preserved.

Maintain Consistent Dosing

The short half-life of tesamorelin requires daily administration for consistent results. Missing doses reduces effectiveness. Set a daily reminder.

Combine With Proper Nutrition

Tesamorelin supports fat loss but works best with a controlled diet. Focus on adequate protein intake and moderate caloric restriction for optimal body composition changes. These protocols are just tools. They are not magic. The foundation still absolutely matters. Training, nutrition, sleep. Get that stuff dialed in before leaning on drugs like tesamorelin to help you put icing on the cake.

Consider IGF-1 Monitoring

Periodic blood tests for IGF-1 levels help ensure the therapy is working and that levels remain within safe ranges. In the clinical trials, IGF-1 levels rose into the mid-normal range within healthy parameters. Work with a healthcare provider familiar with peptide therapy.

Stack Strategically

Tesamorelin pairs well with Ipamorelin, which works through the ghrelin receptor rather than GHRH receptors. Pin them together in the same window. The synergy only happens when both pathways are activated at the same time. GHRP suppresses somatostatin while GHRH drives pituitary output, and that combined signal produces a much larger growth hormone pulse than either one alone. Splitting them into separate doses just gives two smaller separate pulses, which defeats the purpose of stacking.

Do not stack tesamorelin with CJC-1295 or sermorelin. All three are GHRH analogs that bind to the same receptors in your pituitary gland. Same pathway, same mechanism. Stacking them is redundant at best and wastes money. The fact that they are marketed for different benefits does not mean they work differently. Tesamorelin trials measured visceral fat with CT scans while CJC trials only measured growth hormone levels, but the underlying mechanism is identical. Pick one GHRH analog and pair it with ipamorelin.

Do not stack tesamorelin with exogenous growth hormone or IGF-1. Tesamorelin is a secretagogue. It signals your pituitary to release growth hormone. When you inject exogenous GH or IGF-1, your circulating IGF-1 levels rise and your hypothalamus responds by releasing somatostatin. Somatostatin blocks the pituitary from responding to the GHRH signal that tesamorelin is sending. Research showed GHRH pathway compounds were inhibited by 86% and ghrelin pathway compounds were blunted by about 32% after exogenous GH injection. If you are already on HGH or IGF-1, your secretagogues are not adding anything. Secretagogues work within your body’s natural limits and keep your feedback loop intact. Exogenous GH and IGF-1 bypass all of that. Pick one approach based on your goal, do not run both. (Arvat E, et al. “Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.” Metabolism. 1997;46(1):83-8. PMID: 9005975)

Expect Rebound Without Maintenance

Clinical data shows visceral fat can return when tesamorelin is discontinued. The results were sustained as long as patients stayed on the drug, but when they discontinued, some fat reaccumulation did occur over time. Long-term or cyclical use may be necessary to maintain results.

Storage and Handling

CRITICAL: Tesamorelin has unique storage requirements that differ from most peptides.

Before Reconstitution

After Reconstitution (CRITICAL DIFFERENCE)

labeling

Why Room Temperature Storage?

Tesamorelin has unique solubility characteristics. At refrigerator temperatures (2-8°C), the peptide can undergo physical changes including:

This is not a contamination issue—it is a physical property of the tesamorelin molecule itself. The FDA prescribing information for both Egrifta SV and Egrifta WR explicitly states to store reconstituted solution at room temperature and not to refrigerate or freeze.

Important Note on Pharmaceutical vs. Research-Grade Peptides

The FDA storage data applies to pharmaceutical-grade Egrifta, which contains stabilizing excipients (e.g., hydroxypropyl betadex in Egrifta WR) that protect against chemical degradation. Research-grade tesamorelin from peptide suppliers typically lacks these stabilizers but retains the same core molecular structure. The room temperature requirement likely still applies, as it relates to the physical solubility properties of tesamorelin itself. However, stability windows may differ. Use reconstituted research-grade peptides promptly and monitor for any changes in appearance.

If you have been refrigerating your tesamorelin and the solution is still clear and injectable, you likely have not had issues. But if you notice thickening, cloudiness, or gel formation, cold storage is the probable cause. Switch to room temperature storage going forward.

This storage requirement is specific to tesamorelin. Other peptides like CJC-1295, Ipamorelin, BPC-157, and HGH should still be refrigerated after reconstitution per standard peptide guidelines.

Sources:

FDA EGRIFTA WR Prescribing Information (2025): Store reconstituted solution at room temperature 20 to 25 degrees Celsius. Discard 7 days after mixing. Do not freeze.

FDA EGRIFTA SV Prescribing Information: Administer immediately following reconstitution. Do not refrigerate or freeze the reconstituted solution.

Legal Status

United States: Tesamorelin is FDA-approved under the brand names Egrifta SV and Egrifta WR for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It is a prescription medication. Off-label use for other conditions occurs but is not FDA-sanctioned.

World Anti-Doping Agency (WADA): Tesamorelin is prohibited at all times under Section S2: Peptide Hormones, Growth Factors, Related Substances, and Mimetics.

Competitive Athletes: Any athlete subject to drug testing should not use tesamorelin. GHRH and its analogs are banned substances.

Frequently Asked Questions

Is tesamorelin only for HIV patients?

Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. However, research continues in other conditions including NAFLD, general obesity, and cognitive decline. Some practitioners prescribe it off-label for these conditions.

How is tesamorelin different from direct HGH injections?

Tesamorelin stimulates your pituitary to release its own growth hormone, preserving natural pulsatile patterns and feedback mechanisms. Direct HGH injections provide constant supraphysiologic levels that suppress natural production.

Will the fat come back after stopping?

Clinical studies show visceral fat tends to re-accumulate after discontinuing tesamorelin. Long- term or maintenance therapy may be needed to preserve results.

Does tesamorelin affect blood sugar?

Tesamorelin can cause glucose intolerance and may increase the risk of type 2 diabetes in susceptible individuals. Blood glucose should be monitored during therapy, especially in those with prediabetes.

Can I use tesamorelin for weight loss if I do not have HIV?

Tesamorelin is not approved as a general weight loss medication. Some practitioners prescribe it off-label, but this should only be done under medical supervision with appropriate monitoring.

How long until I see results?

Most clinical trials show measurable visceral fat reduction by 26 weeks. Some users report noticing changes in body composition around 8 to 12 weeks.

Can tesamorelin be combined with other peptides?

Yes. Common combinations include tesamorelin with Ipamorelin, which works through a different receptor pathway. Pin them together in the same dosing window for maximum synergy. Do not combine tesamorelin with exogenous growth hormone or IGF-1 because somatostatin feedback will block the secretagogue signal. Always work with a knowledgeable provider when stacking peptides.

Is tesamorelin safer than HGH?

Tesamorelin maintains more natural hormone patterns and feedback mechanisms than direct HGH, which may reduce certain risks. However, both raise IGF-1 levels and share some potential side effects. Neither is completely without risk.

Why does tesamorelin need room temperature storage after reconstitution?

Unlike most peptides, tesamorelin can gel or precipitate at refrigerator temperatures. This is a physical property of the molecule itself. The FDA prescribing information explicitly states to store reconstituted EGRIFTA at room temperature and not to refrigerate. If your reconstituted tesamorelin has gelled, cold storage is likely the cause.

Can I take tesamorelin with exogenous growth hormone or IGF-1?

No. Tesamorelin is a secretagogue that signals your pituitary to release growth hormone. Exogenous GH and IGF-1 raise somatostatin levels, which blocks the pituitary from responding to that signal. Research showed GHRH pathway compounds were inhibited by 86% after a single exogenous GH injection. If you are already on HGH or IGF-1, tesamorelin is not adding anything. Pick one approach based on your goal. (Arvat E, et al. Metabolism. 1997;46(1):83-8. PMID: 9005975)

References

1. Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin, a growth hormone- releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-322. https://pubmed.ncbi.nlm.nih.gov/20065828/ 2. Grunfeld C, Thompson M, Brown SJ, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr. 2007;45(3):286-297. 3. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25038356/ 4. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of Tesamorelin on Nonalcoholic Fatty Liver Disease in HIV: A Randomized, Double-Blind, Multicenter Trial. Ann Intern Med. 2019;171(1):1-10. https://pubmed.ncbi.nlm.nih.gov/31158827/ 5. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. 6. Theratechnologies Inc. Egrifta SV (tesamorelin) Prescribing Information. 2024. 7. Theratechnologies Inc. Egrifta WR (tesamorelin) Prescribing Information. 2025. 8. Arvat E, di Vito L, Broglio F, et al. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man. Metabolism. 1997;46(1):83-88. https://pubmed.ncbi.nlm.nih.gov/9005975/ 9. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Tesamorelin. National Institute of Diabetes and Digestive and Kidney Diseases. 2018. 10. World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List 2024. https://www.wada-ama.org/en/prohibited-list

Property Support

Our Property Support services are designed to help homeowners, property managers, and businesses maintain safe, clean, and well-functioning properties year-round.

Get In Touch